R&D spending rebounds big in 2013

Pharma companies have taken some heat for their R&D productivity levels as of late. But drug developers and investors apparently have seen their faith restored: According to an EY report, R&D spending across the biopharma industry shot up 14% to hit $29.1 billion in 2013, reflecting renewed optimism that research can breed results. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.